Protagonist Therapeutics, Inc. surged 30% after Johnson & Johnson expressed acquisition interest, driven by the need to offset Stelara's declining sales. PTGX's lead assets, Icotrokinra and Rusfertide ...
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the ...
Hosted on MSN
Every Pokémon protagonist’s official name
The Pokémonseries has always allowed for players to choose their trainer's name. But each Pokémon protagonist also has an official, canonical name as well. The option to name the main characters of ...
Ratings for Protagonist Therapeutics (NASDAQ:PTGX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view ...
NEWARK, CA / ACCESS Newswire / March 18, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Johnson & Johnson received U.S. Food and Drug ...
Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results